NAD+ 1G & RETATRUTIDE : A BRITISH REPORT

The recent interest in NAD+ supplementation, particularly at a substantial dosage of 1g , continues to build within the British medical community. Simultaneously , attention is firmly fixed on Retatrutide, a novel GLP-1 analogue being viewed by many as a potential advancement to Tirzepatide. Curr